Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA-based immunotherapies and vaccines for infectious diseases, cancer, and other serious health conditions. Established in 2001, the company advances its research through proprietary DNA delivery technology and seeks to create innovative solutions to address unmet medical needs worldwide.
Company News
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the h...
Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs fr...
Pomerantz LLP has filed a class action lawsuit against Inovio Pharmaceuticals and certain officers for alleged securities fraud. The lawsuit claims defendants made false statements about FDA approval prospects and manufacturing capabilities for their lead product INO-3107. The company delayed BLA submission by a year due to manufacturing issues w...
Law Offices of Howard G. Smith announced securities fraud class action lawsuits against three publicly-traded companies: Paysafe Limited (PSFE) for undisclosed business risks and overstated guidance, Inovio Pharmaceuticals (INO) for deficient manufacturing and overstated regulatory prospects, and Kyndryl Holdings (KD) for misstated financial stat...
A class action lawsuit has been filed against Inovio Pharmaceuticals for allegedly making false and misleading statements regarding manufacturing deficiencies in its CELLECTRA device and overstating regulatory prospects for INO-3107. The FDA accepted Inovio's BLA on a standard review timeline rather than accelerated approval, causing the stock to...
